Takeda Announces Global Discontinuation of HEMOFIL® M and RECOMBINATE®
Important Community Notice from the Hemophilia Foundation of Maryland Takeda Announces Global Discontinuation of HEMOFIL® M and RECOMBINATE® Takeda has announced its decision to globally discontinue HEMOFIL® M [Antihemophilic Factor (Human), Method M, Monoclonal Purified] and RECOMBINATE® [Antihemophilic Factor (Recombinant)]. Takeda recognizes the significant
FDA Approves Subcutaneous Therapy for Hemophilia Patients with Inhibitors
January 2, 2025 The U.S. Food and Drug Administration (FDA) has approved Alhemo (concizumab-mtci) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A
**Important Announcement**
As funding becomes increasingly limited, we must recognize the specialty pharmacies that partner with HFM and financially support our mission. Their partnership and contributions enable us to host events and programs such as Summer Camp, the Milton Doug Hiteshew Scholarship
07/23/2024 – Press Release – Comer Releases Report on PBMs’ Harmful Pricing Tactics and Role in Rising Health Care Costs
WASHINGTON—Today, House Committee on Oversight and Accountability Chairman James Comer (R-Ky.) issued a report outlining how the three largest Pharmacy Benefit Managers (PBMs) —CVS Caremark, Express Scripts, and OptumRx—have monopolized the pharmaceutical marketplace by deploying deliberate, anticompetitive pricing tactics that
Hemophilia Foundation of Maryland (HFM)
13 Class Court Parkville, MD 21234
